NEW YORK: Pfizer has invited the world's three largest marketing holding companies to assemble their strongest PR teams to pitch their cardiovascular franchise.
In addition to Lipitor, Pfizer's cardiovascular unit includes Norvasc, a treatment for hypertension and angina, and Caduet, a dual therapy of Lipitor and Norvasc currently awaiting FDA approval.
Omnicom's Ketchum has had the Lipitor business to itself for the past five years, said Michal Fishman, director of US pharmaceuticals PR for Pfizer. Feinstein Kean Healthcare, a division of Ogilvy ...